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Abstract
Background: There is increasing evidence to support the phenomenon of response shift (RS) in
quality of life (QoL) studies, with many current QoL measures failing to allow for this. If significant
response shift occurs amongst prostate cancer patients, it will be necessary to allow for this in the
design of future clinical research and to reassess the conclusions of previous studies that have not
allowed for this source of bias. This study therefore aimed to assess the presence of RS and
psychosocial morbidity in patients with advanced prostate cancer and their partners.
Methods: 55 consecutive advanced prostate cancer patients and their partners completed the
Prostate Cancer Patient & Partner questionnaire (PPP), shortly after diagnosis and again at 3
months and 6 months. At the follow-up visits, both patients and partners also completed a then-
test in order to assess RS.
Results: Partners consistently showed greater psychological morbidity than patients in relation to
the prostate cancer. This was most marked on the General Cancer Distress (GCD) subscale (p <
0.001, paired t-test), and regarding worries about treatment (p = 0.01). Significant RS was identified
in partners and patients by the use of the then-test technique, particularly on the GCD subscale,
the concerns about treatment and the concerns about urinary symptoms items.
Conclusion: These results suggest the presence of RS in patients with advanced prostate cancer
and their partners, with higher levels of psychosocial morbidity noted amongst partners. This is the
first study to identify RS in partners and calls into question the interpretation of all studies assessing
changes in QoL that fail to allow for this phenomenon.
Background
Quality of life (QoL) assessment is increasingly used as a
major outcome parameter in health care, both for clinical
decisions and policy making. It is vital therefore, that the
measurement of QoL accurately reflects differences
between patient groups, and changes in QoL over time. A
defining characteristic of human beings, however, is the
way in which we adapt to changing circumstances and one
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of the implications of this is the phenomenon of
'response shift' (RS) in self-ratings. The concept of RS orig-
inated in the 1970's in the field of educational measure-
ment [1,2]. GS Howard and colleagues argued that, in
using self-report instruments, researchers assume that
individuals evaluating themselves have an internalised
standard for judging their level of functioning with regard
to a given dimension, and that this internalised standard
will not differ between experimental and control groups
or change from one testing to the next (pre-test to post-
test). However, if the individual's standard of measure-
ment should change between the pre-test and post-test
(due to some form of intervention or change), the two rat-
ings would reflect this difference in addition to any actual
change taking place. Consequently, comparison of the
two ratings will be invalid. Since longitudinal QoL meas-
urement traditionally relies on the comparison of pre- and
post-test questionnaires, usually in patients adapting to
some form of change, this problem calls into question the
interpretation of all data acquired in this manner [3].
Response shift, when applied to the area of QoL, is
defined as a change in the meaning of one's self-evalua-
tion of QoL as a result of: (a) change in the respondent's
internal standards of measurement (recalibration); (b)
change in the respondent's values; or (c) redefinition of
life quality (reconceptualization)[4].
There are many techniques suggested for evaluating RS
[5,6] the most established of these being the retrospective
pre-test design proposed by G. S. Howard [1,2]. The
design consists of:
Pre-test
Assessment at beginning of study, i.e. before intervention
/ change
Post-test
Subsequent assessment, i.e. after intervention / change
Then-test
Retrospective assessment of first evaluation
This retrospective re-evaluation assumes that the subject
uses the same criteria for the conventional post-test and
the then-rating, and thus allows comparison between the
2 assessments: (see Figure 1)
Traditional Change
Difference between pre-test and post-test scores, as would
be measured by standard QoL assessment techniques, i.e.
reported treatment effect.
Response Shift
Difference between pre-test and then-test scores.
Actual Change
Difference between then-test and post-test score, reflect-
ing the change in QoL having allowed for response shift.
The concept of RS is still in its early stages and recent
research has also highlighted a need to focus on a subject's
'appraisal' of QoL, which may be influenced by personal-
ity, culture or situation. Different appraisal parameters
can be measured in relation to the types of RS outlined
above: 1) Change in frame of reference (relate to recon-
ceptualization), 2) Change in recall or sampling of expe-
riences (relate to reprioritization) and 3) Change in
standards of comparison to appraise experience (relate to
recalibration). Indeed a QoL Appraisal Profile has been
proposed for potential use alongside other QoL measures
[7]. Whilst differences in appraisal will undoubtedly exist
if formally measured, their interpretation within the con-
text of modern psychometric models means that these
need not be viewed as sources of error, but instead as proc-
esses integral to the assessment of QoL [8].
Defining the impact of chronic illness on the partners of
patients is a relatively recent endeavour [9]. The ageing
population, changes in medical practice leading to shorter
inpatient hospital stay and prolonged survival, have
resulted in a significantly increased burden being placed
on carers, the majority of whom are partners [10]. The
morbidity of partners of those with chronic illness has
been well described, particularly through qualitative
research [11,12] and has consistently found that the QoL
of the partner is often worse than that of the patient [13-
16]. The first published work on the QoL of spouses of
The then-test approach to measuring response shift (from  Sprangers et al 1999) [27] Figure 1
The then-test approach to measuring response shift (from 
Sprangers et al 1999) [27].
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prostate cancer patients, however, was by Kornblith et al
in 1994 [17]. Problems reported by patients and partners
were of a similar nature, but spouses reported significantly
greater psychological distress than patients, in keeping
with the studies mentioned previously. As a result of these
findings, the Prostate Cancer Patient and Partner Ques-
tionnaire (PPP) was developed to help to identify psy-
chosocial morbidity within both patients and partners
[18]. As part of the validation process, the PPP was admin-
istered to a sequential sample of 135 couples with any
stage of prostate cancer, attending outpatient clinics[19].
The questionnaire is unique in that it was developed and
validated simultaneously in patients and partners, i.e. the
partner component is not an adapted patient
questionnaire.
The aim of this study was to determine whether incorpo-
rating a then-test into the PPP would detect a significant
RS in patients with advanced prostate cancer and/or their
partners. Whilst RS had previously been identified by Rees
et al. in the assessment of lower urinary tract symptoms
amongst a cohort of patients with advanced prostate can-
cer [20], it was not known how such patients would assess
other factors relating to their diagnosis, or how their part-
ners would rate QoL. Two hypotheses were therefore pro-
posed. First, that patients would initially under-report the
impact of both their urinary symptoms (where present)
and diagnosis of prostate cancer on their QoL, then with
adaptation and symptomatic improvement, retrospec-
tively lower their initial QoL scores. Second, that there
would not be a significant RS in partners, predicting that
the higher levels of psychosocial morbidity in previous
partner studies may relate to a lack of adaptation, with the
disease process itself perhaps acting as a catalyst for
response shift in patients. However, with no previous
work on RS in partners, these hypotheses were purely
speculative.
Methods
For the purpose of the study, patients were classified as
having locally advanced disease if they had 2 out of 3 from
the following: (a) PSA > 10 ng/ml, (b) Gleason Grade > 7,
(c) Clinical Stage ≥  T3 [21]. Patients were excluded from
the study if unable to complete the questionnaires, either
through lack of understanding, poor literacy or limited
life expectancy (<6 months). It was also decided that con-
current illness (e.g. another malignancy or severe cardio-
respiratory disease) or concurrent social or emotional
problems would also affect the results of the study, and
patients with these problems should not be included.
Patients were recruited from outpatient clinics in 3 hospi-
tals in the South-West of England (Taunton and Somerset
Hospital, Southmead Hospital and Bristol Royal Infir-
mary). Patients and partners were seen in their own
homes within a week of the patient's initial diagnosis, and
at the first visit completed the PPP (Appendix [see addi-
tional file 1]). Subsequent visits took place 3 months and
6 months later, and following the post-tests at these visits
a then-test was incorporated, with both groups asked to
re-evaluate their QoL at the time of the previous assess-
ment using the PPP. It was emphasised that the then-test
was not asking patients / partners to recall their previous
answers but instead to provide a renewed judgment.
Patients and partners filled in the questionnaires
simultaneously, in the presence of the interviewer, and
were asked not to compare their answers in order to
remove any bias that this might cause.
Results
Between 20th July 2000 and 19th July 2001, 55 patients
and 43 partners gave informed consent to take part in the
study. Despite excluding patients from the study with a
predicted life expectancy less than 6 months, 2 patients
died shortly after their diagnosis, and thus 53 patients and
41 partners completed all 3 assessments.
The mean age of the patients was 72.9 years (SD 8.5,
Range 54 – 92 years). Prostate specific antigen (PSA) lev-
els at presentation ranged from 4.4 to 5050 ng/ml, with a
median of 57.2. Histological diagnosis was made in 46
patients, with 1 well differentiated tumour, 27 moderately
differentiated and 18 poorly differentiated, according to
the Gleason grading system. Nine patients were treated as
a result of a clinical diagnosis alone. Distant metastases
were identified in 13 patients and the remaining 42
patients were therefore considered to have locally
advanced disease. 44 patients received treatment with
hormonal therapy alone (LHRH analogue), whilst 8
patients received radical radiotherapy in addition to their
neo-adjuvant hormonal therapy. Three patients did not
receive treatment during the study, but were placed on an
active surveillance or 'watchful waiting' regime.
General Cancer Distress (GCD) Subscale
Partners showed significantly higher cancer-related dis-
tress (p < 0.001) than patients at all 3 visits (Table 1).
Table 2 examines the use of the then-test, and the impact
of this on what has been termed the 'traditional change'
and 'actual change'. Using a paired t-test, a statistically sig-
nificant difference between the pre-test and then-test
scores was identified at both visits 2 and 3. A significant
change was identified in both patients and partners
between visits 1 and 2 using conventional pre and post-
testing (traditional change), but this change was increased
by the incorporation of the then-test methodology, to a p
value <0.001 for both groups. The traditional change
between visits 2 and 3 was of borderline significance in
both groups, but the addition of the then-test again led to
highly significant actual change (p < 0.001 in bothHealth and Quality of Life Outcomes 2005, 3:21 http://www.hqlo.com/content/3/1/21
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groups). These changes are depicted graphically in Figure
2.
The results showed improvement in 'general cancer dis-
tress' as identified by this questionnaire over the first 6
months following diagnosis (Table 1). In addition to
showing greater degree of worry/concern at all assess-
ments, partners were also seen to undergo a larger RS than
patients. Using a paired t-test this difference between
patients and partners in magnitude of 'response shift' did
not reach statistical significance during the first 3 months
(p = 0.3); however, the difference was statistically signifi-
cant between the second and third assessments (p = 0.02).
Social subscale
Scores on the social subscale were relatively low overall
and no significant difference in mean scores was seen
between patients and partners at visit 1, 2 or the visit 2
then-test. A statistically significant difference was seen,
however, at visit 3, and the then-test at this time also
showed a highly significant difference between patients
and partners (mean score 0.8 versus 2.3 respectively, p <
0.001).
This subscale showed no statistically significant change
with the use of the then-test, except for partners between
visit 2 and 3 (Table 3). However, the additive effect of the
then-test made the actual change on this subscale highly
statistically significant for partners, both between visits 1
and 2, and visits 2 and 3. No significant changes were seen
in patients using this subscale. The greater RS in partners
than patients between visits 2 and 3 was highly statisti-
cally significant (p < 0.001, paired t-test).
Worries about treatment
Partners were statistically significantly more worried than
patients for those receiving treatment, except at the visit 2
then-test (which was based on a very small sample since
Table 1: Mean scores on GCD Subscale for patients and partners
Visit 1 Visit 2 Visit 2 – Then-test Visit 3 Visit 3 – Then-test
Patients Mean (n) 4.4 (55) 3.2 (53) 5.4 (53) 2.6 (53) 4.8 (53)
S.D. 2.7 2.5 2.7 2.0 2.5
Partners Mean (n) 7.8 (43) 6.5 (41) 9.2 (41) 7.2 (38) 9.0 (38)
S.D. 2.4 2.3 2.6 2.3 2.4
Difference* 3.2 3.1 3.7 4.5 4.1
95% C.I. 2.3 – 4.0 2.3 – 4.0 2.6 – 4.7 3.5 – 5.5 3.1 – 5.1
P value** <0.001 <0.001 <0.001 <0.001 <0.001
*Difference in mean scores for the pairs at each visit, i.e. 43 at visit 1
** Paired t-test
Table 2: Changes in scores on the GCD Subscale for patients and partners
Months 0 – 3 Months 3 – 6
Pre-test – Then-test 
('Response Shift') (p*)
Patients (n = 53) 1.0 (0.004) Pre-test – Then-test 
('Response Shift') (p*)
Patients (n = 53) 1.6 (<0.001)
95% C.I. 0.4 – 1.7 95% C.I. 1.0 – 2.2
Partners (n = 41) 1.4 (0.001) Partners (n = 38) 2.6 (<0.001)
95% C.I. 0.6 – 2.3 95% C.I. 1.8 – 3.3
Pre-test – Post-test 
('Traditional Change') (p*)
Patients (n = 53) 1.2 (<0.001) Pre-test – Post-test 
('Traditional Change') (p*)
Patients (n = 53) 0.6 (0.05)
95% C.I. 0.6 – 1.7 95% C.I. 0.0 – 1.1
Partners (n = 41) 1.3 (0.002) Partners (n = 38) -0.7 (0.06)
95% C.I. 0.5 – 2.1 95% C.I. -1.5 – 0.0
Then-test – Post-test 
('Actual Change') (p*)
Patients (n = 53) 2.2 (<0.001) Then-test – Post-test 
('Actual Change') (p*)
Patients (n = 53) 2.2 (<0.001)
95% C.I. 1.6 – 2.8 95% C.I. 1.6 – 2.8
Partners (n = 41) 2.7 (<0.001) Partners (n = 38) 1.8 (<0.001)
95% C.I. 2.0 – 3.4 95% C.I. 1.0 – 2.6
*Paired t-testHealth and Quality of Life Outcomes 2005, 3:21 http://www.hqlo.com/content/3/1/21
Page 5 of 8
(page number not for citation purposes)
few patients had commenced treatment by visit 1). Con-
cerns about treatment would appear not to decline with
traditional pre/post-testing, but the results at the visit 3
then-test were significantly different from the pre-test at
visit 2 in both patients and partners, suggesting a signifi-
cant improvement in treatment related concerns. This dif-
ference was greater in the partners than in the patients (p
= 0.01, paired t-test).
The patients (and their partners) receiving no treatment at
the time of the initial visit showed higher degrees of
worry/concern than those already established on treat-
ment (0.8 versus 0.6 for patients, 2.1 versus 1.6 for part-
ners). Otherwise, the results for this question are difficult
to interpret, due to small numbers at subsequent visits.
Worries about pain
The low number of patients with significant pain limits
the interpretation of these results. Overall, partners
appeared to be more concerned about pain than their hus-
bands, but these differences only reach statistical signifi-
cance with the then-tests. Traditional pre/post-testing
revealed no significant change in either group, but the
incorporation of the then-test resulted in a significant
'actual change' for both patients and partners between vis-
its 1 and 2 (p = 0.03 for patients, p = 0.02 for partners,
paired t-test). The difference in then/pre- test scores
('response shift') between visits 2 and 3 also reaches
statistical significance (p = 0.05 patients, p = 0.04 part-
ners), but otherwise no statistically significant results were
found.
Worries about urinary symptoms
Changes in mean scores on General Cancer Distress Sub- scale in patients and partners Figure 2
Changes in mean scores on General Cancer Distress Sub-
scale in patients and partners.
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Table 3: Changes in scores on the Social Subscale for patients and partners
Months 0 – 3 Months 3 – 6
Pre-test – Then-
test ('Response Shift') 
(p*)
Patients (n = 53) 0.4 (0.1) Pre-test – Then-
test ('Response Shift') 
(p*)
Patients (n = 53) 0.2 (0.1)
95% C.I. -0.1 – 0.8 95% C.I. -0.5 – 0.6
Partners (n = 41) 0.3 (0.3) Partners (n = 38) 1.6 (<0.001)
95% C.I. -0.3 – 0.8 95% C.I. 1.0 – 2.2
Pre-test – Post-test 
('Traditional Change') 
(p*)
Patients (n = 53) 0.04 (0.8) Pre-test – Post-test 
('Traditional Change') 
(p*)
Patients (n = 53) -0.1 (0.6)
95% C.I. -0.3 – 0.3 95% C.I. -0.4 – 0.2
Partners (n = 41) 0.5 (0.02) Partners (n = 38) -0.7 (0.004)
95% C.I. 0.06 – 0.9 95% C.I. -1.2 – 0.2
Then-test – Post-
test ('Actual Change') 
(p*)
Patients (n = 53) 0.4 (0.1) Then-test – Post-
test ('Actual Change') 
(p*)
Patients (n = 53) 0.1 (0.3)
95% C.I. -0.04 – 0.8 95% C.I. -0.3 – 0.1
Partners (n = 41) 0.8 (0.001) Partners (n = 38) 0.9 (0.001)
95% C.I. 0.3 – 1.2 95% C.I. 0.4 – 1.4
*Paired t-testHealth and Quality of Life Outcomes 2005, 3:21 http://www.hqlo.com/content/3/1/21
Page 6 of 8
(page number not for citation purposes)
Partners showed higher levels of concern about urinary
symptoms than the patients. These differences reached
statistical significance at visits 2 and 3, and the visit 2
then-test. The traditional change in worry/concern, as
measured by the pre/post-test design, was non-significant
over both the first and second three-month periods.
However, incorporating the then-test, the actual change in
the first 3 months was significant in both patients and
partners. Patients had a greater actual decrease in concerns
than their partners. In the second 3-month period, tradi-
tional measurement would suggest that both patients and
partners became more concerned about urinary symp-
toms. However, using the then-test methodology, the
actual change in concern was a decrease in both groups.
This decrease did not, however, reach statistical
significance.
Worries about physical limitation
The low proportion of patients with physical limitation
due to their prostate cancer means that although partners
were consistently more concerned, according to their
responses to this question, this did not reach statistical
significance. No significant differences were identified on
analysis of then-test results.
Worries about sexual function
The results for this question show that only 33% of
patients were sexually active at the beginning of this study.
No significant differences were seen between patients and
partners at each assessment, although patients tended to
have higher scores on this question. The only significant
change using the then-test occurs in the patient group,
between visits 2 and 3 (p = 0.01).
Discussion
This study revealed that patients with advanced prostate
cancer retrospectively lowered their QoL scores at both the
3 and 6-month visits. Whilst this was consistent with our
initial hypothesis, it was also noted that partners in some
cases demonstrated significantly worse QoL scores than
the patients (particularly on the General Cancer Distress
scale). In addition, tentative to our second hypothesis, we
observed evidence of RS in the partners of the patients.
Although this was no less than in the patients, partners in
some cases (e.g. Social subscale between visits 2 & 3)
showed a significant RS where patients did not.
These findings confirm the previous evidence in prostate
cancer of higher psychological morbidity amongst part-
ners compared to the patients. The consistency of this
finding in prostate cancer studies and those looking at
other conditions suggests that this is a genuine phenome-
non. Although this could merely represent a difference in
the way QoL questions are answered by men and women,
the literature suggests that male partners are just as likely
to have high levels of psychological morbidity as female
partners. Indeed one study of couples with colon cancer
found that the adjustment of husbands was far worse than
that of wives of cancer patients [22].
The then-test results were statistically significantly differ-
ent from pre-test results on several scales, particularly the
GCD subscale, concerns about treatment and concerns
about urinary symptoms items. Whilst this may provide
an estimate of the magnitude and direction of a RS effect,
the fundamental question is whether these differences
really represent RS or some other confounding factor(s).
Social desirability may play a part in the retrospective
worsening of QoL scores, in which the subject feels their
QoL should have improved with treatment and therefore
they will place lower scores on then-test evaluation. It is
also possible that the patients and partners may feel an
implicit pressure to 'please the doctor', again leading them
to lower their retrospective QoL scores. Although the the-
ory of RS was not explained to the subjects, it is likely that
many will have understood the purpose of then-testing.
In addition, the issue of recall bias and memory must also
be considered in relation to the then-test. Differences in
prospective versus retrospective health assessments may
be due to recall bias [5]. In a study by Ahmed et al assess-
ing patients' QoL following stroke, a memory checklist
was incorporated to provide an objective measure of their
functional ability and so determine the effects of recall
bias on the final results [23]. Whilst patients with 'good'
memory demonstrated large response shifts and those
with 'poor' memory greater variability, a significantly
lower then-test rating was noted in those with stroke, with
no such effect amongst the control group. This implies
that the changes could not be wholly attributed to recall
bias and previous research would support this [24]. Fur-
thermore, in this study an attempt was made to minimise
the effects of recall bias and memory by using relatively
small time differences between assessments (3 months). If
the then-test is performed too close to the pre-test, it is
possible that subjects will remember their previous
answers and score the questionnaire accordingly. Con-
versely, if the then-test is performed at a later time-inter-
val, it is possible that memory effects may have an
increasing role. The effect of changes in timing of the
then-test is an interesting area for future research.
It would therefore appear safe to conclude that a substan-
tial part of the difference seen between pre and then-test
scores can be explained by RS. As mentioned above, the
GCD subscale, concerns about treatment and urinary
symptoms items showed statistically significant change,
for both patients and partners, suggesting that a RS was
occurring in these areas in both groups. Incorporating the
then-test tended to increase the magnitude of the changesHealth and Quality of Life Outcomes 2005, 3:21 http://www.hqlo.com/content/3/1/21
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measured using the pre / post-test method, and in many
cases led these changes to become statistically significant.
No formal adjustment was made for multiple testing and
it is therefore possible that some results were artefactual.
However, most of the results reported as significant
involved low probability values suggesting that chance
was an unlikely explanation.
As highlighted earlier, in some cases partners demon-
strated a significant RS, where patients did not. However,
this could represent a phenomenon unique to the PPP
questionnaire, and it would be interesting to study this
effect using other validated QoL questionnaires. It is pos-
sible that the wording of the PPP, concentrating on wor-
ries and concerns, is actually looking at anxiety levels in
both patients and partners, an organic condition in itself,
thus giving both groups a catalyst for a RS as measured by
the questionnaire.
Previous studies have shown that self-reported QoL of
seriously ill patients is higher (i.e. better) than the
patients' proxies (e.g. their partners) believe them to be
[25]. This finding has been explained with reference to RS.
The findings of this study raise the question as to whether
partners in this study, whilst undergoing a response shift
in terms of their own levels of psychological morbidity,
would also recognise a RS on assessing their partners
QoL?
The identification of significant RS in both groups taking
part in this study calls into question the interpretation of
studies that do not allow for its presence. Particularly in
clinical trials, the measurement of differences in QoL
across treatment arms may be jeopardised when RS affects
the treatment groups differently [26]. Since this is a rela-
tively new concept from a methodological viewpoint, it
remains unclear to what extent response shift occurs in
different settings, but research in the area is emerging [27-
29].
Conclusion
This study highlights the presence of RS in both patients
with advanced prostate cancer and their partners, with
higher levels of psychosocial morbidity seen amongst the
partners. This is the first study to identify RS in partners
and not only calls into question the interpretation of stud-
ies assessing changes in QoL, but also raises the question
as to whether RS of this type could actually be identified
as a therapeutic goal, both in chronically ill patients and
their partners.
Authors' Contributions
JR was involved in the design of the study, acquisition of
data and subsequent analysis and interpretation. MC par-
ticipated in the study coordination and drafting the man-
uscript. DW participated in study design and data
interpretation. CO'B helped conceive & design study in
addition to data interpretation. PE performed statistical
analysis. RM helped conceive, design and coordinate
study. All authors approved the final manuscript.
Additional material
Acknowledgements
The authors would like to thank Messrs D. Gillatt (Southmead Hospital) 
and R. Persad (Bristol Royal Infirmary) for access to their patients, and their 
Clinical Research Fellows, Messrs M. Sugiono, J. P. Meyer and B. Patel for 
their assistance in recruiting patients for the study. They are also grateful 
to Dr. M. R. M. Visser, of the Academic Hospital University of Amsterdam 
for her advice regarding the first draft of this paper.
References
1. Howard GS, Ralph KM, Gulanik NA, Maxwell SE, Nance DW, Gerber
SK: Internal invalidity in pre-test – post-test self-report eval-
uations and a re-evaluation of retrospective pre-tests. Appl
Psychol Meas 1979, 3:1-23.
2. Howard GS, Schmeck RR, Bray JH: Internal invalidity in studies
employing self-report instruments: a suggested remedy.  J
Educ Meas 1979, 16:129-135.
3. Breetvelt IS, Van Dam FS: Underreporting by cancer patients:
the case of response-shift. Soc Sci Med 1991, 32:981-987.
4. Sprangers MA, Schwartz CE: Integrating response shift into
health-related quality of life research: a theoretical model.
Soc Sci Med 1999, 48:1507-1515.
5. Schwartz CE, Sprangers MA: Methodological approaches for
assessing response shift in longitudinal health-related qual-
ity-of-life research. Soc Sci Med 1999, 48:1531-1548.
6. Sprangers MA, VanDam FSAM, Broersen J, Lodder L, L W, Visser MR,
Oosterveld P, Smets EM: Response shift and fatigue: The use of
the then-test approach. In Adaptation to changing health: Response
shift in quality of life research Edited by: Schwartz CE and Sprangers MA.
Washington DC, American Psychological Association; 2000. 
7. Rapkin BD, Schwartz CE: Toward a theoretical model of qual-
ity-of-life appraisal: Implications of findings from studies of
response shift. Health Qual Life Outcomes 2004, 2:14.
8. Schwartz CE, Rapkin BD: Reconsidering the psychometrics of
quality of life assessment in light of response shift and
appraisal. Health Qual Life Outcomes 2004, 2:16.
9. Rees J, O'Boyle C, MacDonagh R: Quality of life: impact of
chronic illness on the partner. J R Soc Med 2001, 94:563-566.
10. Ell KO, Nishimoto RH, Mantell JE, Hamovitch MB: Psychological
adaptation to cancer: A comparison among patients,
spouses and nonspouses. Family Systems Medicine 1988, 6:335-348.
11. Nijboer C, Triemstra M, Tempelaar R, Sanderman R, Van den Bos
GA:  Determinants of caregiving experiences and mental
health of partners of cancer patients. Cancer 1999, 86:577-588.
12. Northouse LL, Swain MA: Adjustment of patients and husbands
to the initial impact of breast cancer.  Nurs Res 1987,
36:221-225.
13. Weitzenkamp DA, Gerhart KA, Charlifue SW, Whiteneck GG, Savic
G: Spouses of spinal cord injury survivors: the added impact
of caregiving. Arch Phys Med Rehabil 1997, 78:822-827.
14. Hinton J: Can home care maintain an acceptable quality of life
for patients with terminal cancer and their relatives? Palliat
Med 1994, 8:183-196.
Additional File 1
The Prostate Cancer Patient and Partner Questionnaire (PPP)
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7525-3-21-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Health and Quality of Life Outcomes 2005, 3:21 http://www.hqlo.com/content/3/1/21
Page 8 of 8
(page number not for citation purposes)
15. Axelsson B, Sjoden PO: Quality of life of cancer patients and
their spouses in palliative home care. Palliat Med 1998, 12:29-39.
16. das Chagas Medeiros MM, Ferraz MB, Quaresma MR: The effect of
rheumatoid arthritis on the quality of life of primary
caregivers. J Rheumatol 2000, 27:76-83.
17. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC: Quality
of life of patients with prostate cancer and their spouses. The
value of a data base in clinical care. Cancer 1994, 73:2791-2802.
18. Cliff AM, MacDonagh RP: Psychosocial morbidity in prostate
cancer: I. Design of a new questionnaire.  BJU Int 2000,
86:829-833.
19. Cliff AM, MacDonagh RP: Psychosocial morbidity in prostate
cancer: II. A comparison of patients and partners. BJU Int 2000,
86:834-839.
20. Rees J, Waldron D, O'Boyle C, Ewings P, MacDonagh R: Prospec-
tive vs retrospective assessment of lower urinary tract
symptoms in patients with advanced prostate cancer: the
effect of 'response shift'. BJU Int 2003, 92:703-706.
21. Roach MIII: Management of locally advanced prostate cancer:
new definitions and strategies. West J Med 1998, 169:290-291.
22. Baider L, Perez T, De Nour AK: Gender and adjustment to
chronic disease. A study of couples with colon cancer. Gen
Hosp Psychiatry 1989, 11:1-8.
23. Ahmed S, Mayo NE, Wood-Dauphinee S, Hanley JA, Cohen SR:
Response shift influenced estimates of change in health-
related quality of life poststroke.  J Clin Epidemiol 2004,
57:561-570.
24. Howard GS, Dailey PR: Response-shift bias: a source of contam-
ination of self-report measures. J Appl Psychol 1979, 64:144-150.
25. Tsevat J, Cook EF, Green ML, Matchar DB, Dawson NV, Broste SK,
Wu AW, Phillips RS, Oye RK, Goldman L: Health values of the
seriously ill. SUPPORT investigators.  Ann Intern Med 1995,
122:514-520.
26. Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA:
Assessing meaningful change in quality of life over time: a
users' guide for clinicians. Mayo Clin Proc 2002, 77:561-571.
27. Sprangers MA, Van Dam FS, Broersen J, Lodder L, Wever L, Visser
MR, Oosterveld P, Smets EM: Revealing response shift in longi-
tudinal research on fatigue--the use of the thentest
approach. Acta Oncol 1999, 38:709-718.
28. Bernhard J, Hurny C, Maibach R, Herrmann R, Laffer U: Quality of
life as subjective experience: reframing of perception in
patients with colon cancer undergoing radical resection with
or without adjuvant chemotherapy. Swiss Group for Clinical
Cancer Research (SAKK). Ann Oncol 1999, 10:775-782.
29. O'Boyle C, McGee HM, Browne JP: Measuring response shift
using the Schedule for the Evaluation of Individual Quality of
Life. In Adaptation to changing health: Response shift in quality of life
research Edited by: Schwartz CE and Sprangers MA. Washington,
American Psychological Association; 2000. 